These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 24879506)
1. Novel 3-arylethynyl-substituted thieno[3,4-b]pyrazine derivatives as human transglutaminase 2 inhibitors. Kim N; Kwak SH; Lee SH; Juvekar V; Lee BI; Ahn HC; Kim SY; Gong YD Org Biomol Chem; 2014 Jul; 12(27):4932-40. PubMed ID: 24879506 [TBL] [Abstract][Full Text] [Related]
2. A novel 3-arylethynyl-substituted pyrido[2,3,-b]pyrazine derivatives and pharmacophore model as Wnt2/β-catenin pathway inhibitors in non-small-cell lung cancer cell lines. Gong YD; Dong MS; Lee SB; Kim N; Bae MS; Kang NS Bioorg Med Chem; 2011 Sep; 19(18):5639-47. PubMed ID: 21855350 [TBL] [Abstract][Full Text] [Related]
3. Novel 5,7-disubstituted 6-amino-5H-pyrrolo[3,2-b]pyrazine-2,3-dicarbonitriles, the promising protein kinase inhibitors with antiproliferative activity. Dubinina GG; Platonov MO; Golovach SM; Borysko PO; Tolmachov AO; Volovenko YM Eur J Med Chem; 2006 Jun; 41(6):727-37. PubMed ID: 16675067 [TBL] [Abstract][Full Text] [Related]
4. Anti-cancer effect of a quinoxaline derivative GK13 as a transglutaminase 2 inhibitor. Lee SH; Kim N; Kim SJ; Song J; Gong YD; Kim SY J Cancer Res Clin Oncol; 2013 Aug; 139(8):1279-94. PubMed ID: 23604466 [TBL] [Abstract][Full Text] [Related]
5. Glucosamine is an effective chemo-sensitizer via transglutaminase 2 inhibition. Kim DS; Park KS; Jeong KC; Lee BI; Lee CH; Kim SY Cancer Lett; 2009 Jan; 273(2):243-9. PubMed ID: 18804908 [TBL] [Abstract][Full Text] [Related]
6. Allosteric inhibition site of transglutaminase 2 is unveiled in the N terminus. Kim N; Kang JH; Lee WK; Kim SG; Lee JS; Lee SH; Park JB; Kim KH; Gong YD; Hwang KY; Kim SY Amino Acids; 2018 Nov; 50(11):1583-1594. PubMed ID: 30105541 [TBL] [Abstract][Full Text] [Related]
7. Structure activity relationship studies of imidazo[1,2-a]pyrazine derivatives against cancer cell lines. Myadaraboina S; Alla M; Saddanapu V; Bommena VR; Addlagatta A Eur J Med Chem; 2010 Nov; 45(11):5208-16. PubMed ID: 20832916 [TBL] [Abstract][Full Text] [Related]
9. Reversible and competitive cinnamoyl triazole inhibitors of tissue transglutaminase. Pardin C; Roy I; Lubell WD; Keillor JW Chem Biol Drug Des; 2008 Sep; 72(3):189-96. PubMed ID: 18715232 [TBL] [Abstract][Full Text] [Related]
10. GTP, an inhibitor of transglutaminases, is hydrolyzed by tissue-type transglutaminase (TGase 2) but not by epidermal-type transglutaminase (TGase 3). Hitomi K; Ikura K; Maki M Biosci Biotechnol Biochem; 2000 Mar; 64(3):657-9. PubMed ID: 10803976 [TBL] [Abstract][Full Text] [Related]
11. Discovery of a novel target for renal cell carcinoma: transglutaminase 2. Kang JH; Lee SH; Kim SY Cell Death Dis; 2016 Apr; 7(4):e2200. PubMed ID: 27100894 [No Abstract] [Full Text] [Related]
12. Design, synthesis and biological evaluation of heterocyclic azoles derivatives containing pyrazine moiety as potential telomerase inhibitors. Zhang YB; Wang XL; Liu W; Yang YS; Tang JF; Zhu HL Bioorg Med Chem; 2012 Nov; 20(21):6356-65. PubMed ID: 23018096 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and c-Src inhibitory activity of imidazo[1,5-a]pyrazine derivatives as an agent for treatment of acute ischemic stroke. Mukaiyama H; Nishimura T; Kobayashi S; Ozawa T; Kamada N; Komatsu Y; Kikuchi S; Oonota H; Kusama H Bioorg Med Chem; 2007 Jan; 15(2):868-85. PubMed ID: 17095233 [TBL] [Abstract][Full Text] [Related]
14. Novel imidazo[1,2-a]pyrazine derivatives as potent reversible inhibitors of the gastric H+/K+-ATPase. Zimmermann PJ; Brehm C; Buhr W; Palmer AM; Volz J; Simon WA Bioorg Med Chem; 2008 Jan; 16(1):536-41. PubMed ID: 17964794 [TBL] [Abstract][Full Text] [Related]
15. New target against inflammatory diseases: transglutaminase 2. Kim SY Arch Immunol Ther Exp (Warsz); 2004; 52(5):332-7. PubMed ID: 15507874 [TBL] [Abstract][Full Text] [Related]